Literature DB >> 3526887

Hepatic veno-occlusive disease.

B J Rollins.   

Abstract

Hepatic veno-occlusive disease is a nonthrombotic obliteration of small intrahepatic veins by loose connective tissue. The venous occlusion may be progressive and lead to massive hepatocellular necrosis. Although originally described as a result of intoxication with plant alkaloids, it is now seen as a complication of high-dose antineoplastic chemotherapy, especially in the setting of bone marrow transplantation. The incidence of hepatic veno-occlusive disease after bone marrow transplantation approaches 20 percent, with mortality ranging from 7 to 50 percent. The clinical diagnosis may be quite accurate (as confirmed by biopsy or autopsy) and is based on the triad of jaundice, hepatomegaly and/or right upper quadrant pain, and ascites or unexplained weight gain. The pathogenesis is obscure but most likely relates to drug-induced venous endothelial damage. At the present time, therapy for veno-occlusive disease of the liver remains supportive. As intensive chemotherapy regimens (with or without bone marrow support) become more widely applied, it is expected that this disease will be encountered more frequently.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526887     DOI: 10.1016/0002-9343(86)90266-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Venoocclusive disease of the liver following renal transplantation.

Authors:  M A Jeffries; W M McDonnell; J A Tworek; R M Merion; R H Moseley
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

3.  Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis.

Authors:  D E Lemley; L M DeLacy; L B Seeff; K G Ishak; D J Nashel
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

4.  High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.

Authors:  R B Jones; E J Shpall; M Ross; D Coniglio; M L Affronti; W P Peters
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.

Authors:  L B Grochow; R J Jones; R B Brundrett; H G Braine; T L Chen; R Saral; G W Santos; O M Colvin
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Reversible hepatic dysfunction in association with cyclophosphamide therapy.

Authors:  D V Milford; N Butler; R Clarke; J Vaid
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

Review 7.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

8.  Diagnosis and follow-up of veno-occlusive disease of the liver by use of Doppler ultrasound. A case report.

Authors:  M M Zieger; E Koscielniak
Journal:  Pediatr Radiol       Date:  1993

Review 9.  Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.

Authors:  Cecilia M Choi; Alvin H Schmaier; Michael R Snell; Hillard M Lazarus
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Non-infectious pulmonary complications after bone marrow transplantation.

Authors:  I Khurshid; L C Anderson
Journal:  Postgrad Med J       Date:  2002-05       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.